These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14975547)

  • 1. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center.
    Li ZQ; Cheng TO; Zhang WW; Qiao SB; Zhao LY; Jin YZ; Guan RM; Liu L
    Int J Cardiol; 2004 Feb; 93(2-3):197-202. PubMed ID: 14975547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy].
    Qiao SB; Gao RL; You SJ; Yuan JS; Chen JL; Yang YJ
    Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):210-2. PubMed ID: 16624154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Veselka J; Honek T
    Int J Cardiol; 2003 Mar; 88(1):27-32. PubMed ID: 12659981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy--a meta analysis.
    Zeng Z; Wang F; Dou X; Zhang S; Pu J
    Int J Cardiol; 2006 Sep; 112(1):80-4. PubMed ID: 16507323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients.
    Guo H; Wang J; Chen J; Shan J; Lee JD; Ueda T
    Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
    Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S
    J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful percutaneous transluminal septal myocardial ablation through a right superior septal artery for a patient with hypertrophic obstructive cardiomyopathy.
    Kurita T; Tsuchikane E; Tanaka N; Suzuki T
    Cardiovasc Interv Ther; 2015 Oct; 30(4):377-81. PubMed ID: 25502014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets.
    van der Lee C; ten Cate FJ; Geleijnse ML; Kofflard MJ; Pedone C; van Herwerden LA; Biagini E; Vletter WB; Serruys PW
    Circulation; 2005 Jul; 112(4):482-8. PubMed ID: 16027255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery.
    Qin JX; Shiota T; Lever HM; Kapadia SR; Sitges M; Rubin DN; Bauer F; Greenberg NL; Agler DA; Drinko JK; Martin M; Tuzcu EM; Smedira NG; Lytle B; Thomas JD
    J Am Coll Cardiol; 2001 Dec; 38(7):1994-2000. PubMed ID: 11738306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Percutaneous transluminal septal myocardial ablation: early results and long-term follow-up].
    Tekieli Ł; Pieniazek P; Podolec P; Tomkiewicz-Pajak L; Płazak W; Musiałek P; Leśniak-Sobelga A; Przewłocki T; Biernacka B; Zmudka K; Tracz W
    Przegl Lek; 2006; 63(8):628-32. PubMed ID: 17441371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation.
    Malek LA; Chojnowska L; Klopotowski M; Maczynska R; Demkow M; Witkowski A; Kusmierczyk B; Piotrowicz E; Konka M; Dabrowski M; Ruzyllo W
    Eur J Heart Fail; 2008 Nov; 10(11):1123-6. PubMed ID: 18840395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myocardial perfusion evaluation post percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy by ⁹⁹Tc(m) MIBI SPECT MPI].
    Sun XX; Tian YQ; Qiao SB; Yuan JS; Duan FJ; Wang DY; Guo F; He ZX
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jun; 39(6):497-502. PubMed ID: 21924073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography].
    Faber L; Seggewiss H; Fassbender D; Bogunovic N; Strick S; Schmidt HK; Gleichmann U
    Z Kardiol; 1998 Mar; 87(3):191-201. PubMed ID: 9586154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous transluminal septal myocardial ablation: past, present, and future.
    Maekawa Y; Takamisawa I; Takano H; Takayama M
    J Cardiol; 2022 Sep; 80(3):211-217. PubMed ID: 34924238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [One-year follow-up after echocardiographically-guided percutaneous septal ablation in hypertrophic obstructive cardiomyopathy].
    Seggewiss H; Faber L; Ziemssen P; Gleichmann U
    Dtsch Med Wochenschr; 2001 Apr; 126(15):424-30. PubMed ID: 11347004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy--results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing].
    Krejcí J; Groch L; Meluzín J; Vykypel T; Halámek J; Vitovec J
    Vnitr Lek; 2006 Apr; 52(4):313-20. PubMed ID: 16755987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging of microvascular obstruction in hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation.
    Amano Y; Kitamura M; Yamada F; Aita K; Takayama M; Tachi M; Kumita S
    Acta Radiol; 2015 Nov; 56(11):1323-8. PubMed ID: 25414371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed electrocardiographic changes after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
    Guo H; Wang P; Xing Y; Peng F; Jiang J; Yang B; You B; Qiu Y; Lee JD
    J Electrocardiol; 2007 Oct; 40(4):356.e1-6. PubMed ID: 17316677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse remodeling after percutaneous transluminal septal myocardial ablation in severe but asymptomatic LVOT obstruction (RASTA) study: Rationale and design of transcatheter septal reduction in asymptomatic patients with severe hypertrophic obstructive cardiomyopathy.
    Arslan F; Akdim F; Ten Berg JM
    Catheter Cardiovasc Interv; 2021 Feb; 97(3):488-492. PubMed ID: 32808736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.